Faculty Disclosures
			
				| Jeffrey R. Buchhalter, MD, FAAN | Dr. Buchhalter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Epilepsy Foundation. Dr. Buchhalter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epilepsy Study Consortium. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biocodex. Dr. Buchhalter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurona. | 
			
				| Orrin Devinsky, MD, FAAN | Dr. Devinsky has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Devinsky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for California Cannabis Enterprises. Dr. Devinsky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Engage. Dr. Devinsky has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Privateer Holdings. Dr. Devinsky has received personal compensation in the range of $1,000,000+ for serving on a Scientific Advisory or Data Safety Monitoring board for Receptor Holdings. Dr. Devinsky has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rettco. Dr. Devinsky has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Silver Spike. Dr. Devinsky has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tevard. Dr. Devinsky has received personal compensation in the range of $1,000,000+ for serving on a Scientific Advisory or Data Safety Monitoring board for Tilray. Dr. Devinsky has received personal compensation in the range of $100,000-$499,999 for serving as an officer or member of the Board of Directors for Engage. Dr. Devinsky has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Tevard Biosciences. Dr. Devinsky has stock in Engage. Dr. Devinsky has stock in Empatica. Dr. Devinsky has stock in California Cannabis Enterprises. Dr. Devinsky has stock in Empatica. Dr. Devinsky has stock in Silver Spike. Dr. Devinsky has stock in Docklight Brands. Dr. Devinsky has stock in Egg Rock/Papa Barkley. Dr. Devinsky has stock in Leafly. Dr. Devinsky has stock in Left Coast Ventures. Dr. Devinsky has stock in Privateer Holdings. Dr. Devinsky has stock in Receptor Holdings. Dr. Devinsky has stock in Qstate.  The institution of Dr. Devinsky has received research support from GW Pharma.  The institution of Dr. Devinsky has received research support from Zogenix.  The institution of Dr. Devinsky has received research support from PTC Pharma.  The institution of Dr. Devinsky has received research support from NIH.  The institution of Dr. Devinsky has received research support from DOD.  The institution of Dr. Devinsky has received research support from NIH.  The institution of Dr. Devinsky has received research support from Epilepsy Foundation.  The institution of Dr. Devinsky has received research support from NIH.  The institution of Dr. Devinsky has received research support from NIH.  The institution of Dr. Devinsky has received research support from NSF. Dr. Devinsky has received intellectual property interests from a discovery or technology relating to health care. Dr. Devinsky has received intellectual property interests from a discovery or technology relating to health care. Dr. Devinsky has received publishing royalties from a publication relating to health care. | 
			
				| Jacqueline French, MD, FAAN | Dr. French has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Epilepsy Foundation.  The institution of Dr. French has received research support from Epilepsy Study Consortium/ Epilepsy Foundation (Funded by UCB).  The institution of Dr. French has received research support from GW/One8 Foundation/FACES.  The institution of Dr. French has received research support from NINDS.  The institution of Dr. French has received research support from Xenon.  The institution of Dr. French has received research support from Cerevel.  The institution of Dr. French has received research support from FACES.  The institution of Dr. French has received research support from UCB.  The institution of Dr. French has received research support from Epilepsy Study Consortium.  The institution of Dr. French has received research support from UCB.  The institution of Dr. French has received research support from Praxis. Dr. French has received personal compensation in the range of $50,000-$99,999 for serving as a Chief Medical/Innovation Officer with Epilepsy Foundation. Dr. French has a non-compensated relationship as a Consultant with Acadia Pharmaceuticals Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Access Industries that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Acuta Capital Partners LLC that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with AFASCI Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Agrithera, Inc. that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Alkermes  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Alterity Therapeutics Limited that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Angelini Pharma S.p.A. that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Autifony Therapeutics Limited that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Axonis Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Bain Capital that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Beacon Biosciences that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Biogen that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Biohaven Pharma that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Bloom Science, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Bright Minds Biosciences, Inc. that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Capsidia Biotherapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board with Cerebral Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Cerecin, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with Cerevel that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting, SAB with Cognizance Biomarkers that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Ceribell that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Cowen that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Crossject that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Advisory Board  with EcoR1 Capital that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with EG 427 that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant, Advisory Board  with Eisai that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Encoded Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant/Advisory Board  with Engrail that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Epitel, Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with EpiMinder that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Grin Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Harmony that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Advisory Board  with Ionis Pharmaceutical  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with iQure Pharma, Inc  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with IQVIA that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Janssen Pharma that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Jazz Pharmaceutical  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Leal Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, with Livanova  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, SAB with London Research & Pharmaceuticals  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Longboard Pharmaceutical  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Maplight Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Marinus  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Medscape/Web MD  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Modulight Bio that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Montara Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Mosaica Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Neumarker that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Neumirna Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Neurelis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consulting, Advisory Board  with Neurocrine  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consultant with Neuropace  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with NeuroPro Therapeutics that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Neuroventis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting  with Neurona Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting, Advisory Board  with Neuvarti  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Noema  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Ono Pharmaceutical  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting, Advisory Board  with Otsuka  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a consulting, Advisory Board  with Ovid Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consulting with Praxis that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with PureTech LYT Inc that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with QurAlis Corp that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Rapport Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Receptor Holdings, Inc  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Rivervest Venture Partners  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Sage Therapeutics, Inc  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with SK Life Science  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Stoke  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Stream Neuroscience  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Supernus that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Takeda  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Taysha Gene Therapies  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with UCB, Inc  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with uniQure  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Ventus Therapeutics  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant with Vida Ventures Management  that is relevant to AAN interests or activities. Dr. French has a non-compensated relationship as a Consultant, Advisory Board  with Xenon Pharmaceuticals  that is relevant to AAN interests or activities. | 
			
				| Ruben I. Kuzniecky, MD, FAAN | Dr. Kuzniecky has nothing to disclose. | 
			
				| Pradeep K. Sahota, MD, FAAN | The institution of Dr. Sahota has received research support from VA Merit award. | 
			
				| Michael R. Sperling, MD, FAAN | Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis.  The institution of Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for International Medical Press. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Projects for Knowledge.  The institution of Dr. Sperling has received research support from SK Life Science.  The institution of Dr. Sperling has received research support from UCB Pharma .  The institution of Dr. Sperling has received research support from Takeda.  The institution of Dr. Sperling has received research support from Neurelis.  The institution of Dr. Sperling has received research support from Engage Therapeutics .  The institution of Dr. Sperling has received research support from Medtronic.  The institution of Dr. Sperling has received research support from Cavion.  The institution of Dr. Sperling has received research support from Xenon Pharma.  The institution of Dr. Sperling has received research support from Cerevel.  The institution of Dr. Sperling has received research support from National Institutes of Health .  The institution of Dr. Sperling has received research support from DARPA. Dr. Sperling has received publishing royalties from a publication relating to health care. Dr. Sperling has received publishing royalties from a publication relating to health care. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Vice President  with Epilepsy Consortium . | 
			
				| Paul C. Van Ness, MD, FAAN | No disclosure on file | 
			
				| John S. Duncan, MD | No disclosure on file | 
			
				| Ramon R. Diaz-Arrastia, MD, PhD, FAAN | Dr. Diaz-Arrastia has stock in BrainBox, LLC. Dr. Diaz-Arrastia has stock in Nia Therpeutics.  The institution of Dr. Diaz-Arrastia has received research support from National Institutes of Health.  The institution of Dr. Diaz-Arrastia has received research support from Department of Defense. | 
			
				| Carlos A. Guerreiro, MD, FAAN | No disclosure on file | 
			
				| Mark Agostini, MD | Dr. Agostini has nothing to disclose. | 
			
				| Marilisa M. Guerreiro, MD | No disclosure on file | 
			
				| Imran I. Ali, MD, FAAN | Dr. Ali has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for ABPN. | 
			
				| Matthias J. Koepp, MD, PhD | Dr. Koepp has stock in PrevEp.  The institution of Dr. Koepp has received research support from Wellcome Trust. | 
			
				| Fernando Cendes, MD, PhD, FAAN | Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Biopharma. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for United Medical – Brazil. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Zodiac Pharma . Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Eurofarma – Brazil . Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsia. Dr. Cendes has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers in Neurology - Epilepsy.  The institution of Dr. Cendes has received research support from São Paulo Research Foundation - FAPESP.  The institution of Dr. Cendes has received research support from Conselho Nacional de Desenvolvimento Científico e Tecnológico  - Brazil .  The institution of Dr. Cendes has received research support from NIH. | 
			
				| Iscia Lopes-Cendes, MD, PhD | No disclosure on file | 
			
				| Amit Verma, MD, MBBS, FAAN | No disclosure on file | 
			
				| Mark Richardson, MD, MRCP | The institution of Dr. Richardson has received research support from Medical Research Council UK.  The institution of Dr. Richardson has received research support from Epilepsy Research UK.  The institution of Dr. Richardson has received research support from GW Pharma.  The institution of Dr. Richardson has received research support from European Commission.  The institution of Dr. Richardson has received research support from Autifony Therapeutics .  The institution of Dr. Richardson has received research support from Epilepsy Foundation of America . Dr. Richardson has received intellectual property interests from a discovery or technology relating to health care. | 
			
				| Pradeep N. Modur, MD | No disclosure on file | 
			
				| Li M. Li, MD | No disclosure on file | 
			
				| Eric Halgren, PhD | No disclosure on file | 
			
				| A. LeBron Paige, MD | No disclosure on file | 
			
				| Chad Carlson, MD, FAAN | Dr. Carlson has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant with US Department of Justice. | 
			
				| Luiz E. Betting | Dr. Betting has nothing to disclose. | 
			
				| Puneet K. Gupta, MD | No disclosure on file | 
			
				| Lara V. Marcuse, Sr., MD | Dr. Marcuse has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neuropace. | 
			
				|  | No disclosure on file | 
			
				| Frank Williams | No disclosure on file | 
			
				| Mehdi Soltani, MD | No disclosure on file | 
			
				| Kan Ding, MD | The institution of Dr. Ding has received research support from National Institute of Aging.  The institution of Dr. Ding has received research support from NINDS. | 
			
				| Christof Karmonik, PhD | No disclosure on file | 
			
				| Mahesh M. Thakkar | No disclosure on file | 
			
				| Mario F. Dulay, PhD | No disclosure on file | 
			
				| Matthew Warner | No disclosure on file | 
			
				| Maria C. Soladana, MD | No disclosure on file | 
			
				| Ashok J. Dayananthan, MD | No disclosure on file | 
			
				| Thomas Thesen, PhD | Prof. Thesen has nothing to disclose. | 
			
				| Shivika Chandra, MD, FAAN | The institution of Dr. Chandra has received research support from American Board of Psychiatry and Neurology Faculty Innovation in 好色先生 Award.  The institution of Dr. Chandra has received research support from Michael J Fox Foundation. |